Gilead Sciences Inc —— 图表、价格与新闻 (NASDAQ:GILD)

展开完整图表

Financials

概览声明统计股息

每季度年度

Market Capitalization 173.92 B
Employee 17 K
Founded 1987
CEO Daniel O'Day
Website www.gilead.com
Headquarter Delaware, United States
FIGI BBG000CKGBP2
Industry Technology

总收入

净利润

每股基本收益（基本 EPS）

总债务

自由现金流

现金及现金等价物

173.92 B 市值

市盈率

18.1

市销率

5.23

每股股息

3.16

股息收益率 %

2.57

Gilead Sciences Inc

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s. However, it came under heavy scrutiny over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world.